secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001193125-24-227940
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Biomea Fusion's BMF-219 for type 2 and type 1 diabetes trials
--------------------------------------------------------------------------------

- FDA lifted clinical hold on Phase I/II trials COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) as of Sept 26, 2024.
- CEO stated safety signals from Phase 2a Escalation Study did not translate to Phase 2b Expansion Study; no confirmed serious liver injury.
- Company expects to announce a third development candidate (oral GLP-1 agonist) in Q4 2024.
- Topline Week 26 data from ~200-patient Phase 2b COVALENT-111 and Phase 2a COVALENT-112 (20 patients) expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/0001193125-24-227940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/d310466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-227940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer